VTRS Viatris
Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. It provides access to medicines, advance sustainable operations, develop innovative solutions and leverage its collective expertise to connect more people to more products and services through its one-of-a-kind Global Healthcare GatewayTM. Formed in November 2020through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghaiand Hyderabad, India.
Company profile
Ticker
VTRS, 0A5V
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Upjohn Inc
SEC CIK
Corporate docs
IRS number
834364296
VTRS stock data
()
News
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul 21
Viatris Stock Gains After FDA Approves Viatris-Biocon Biologics' Insulin Glargine Biosimilar Injection
29 Jul 21
10 Worst Performing S&P 500 Stocks Of 2021
2 Jul 21
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
24 Jun 21
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
15 Jun 21
Press releases
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
28 Jul 21
Mylan Wins Dismissal of Kansas EpiPen® Direct Purchaser Case
27 Jul 21
Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021
8 Jul 21
Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action
23 Jun 21
Viatris Inc. to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
25 May 21
Calendar
10 May 21
31 Jul 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
Financial data from Viatris earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 813.1M | 813.1M | 813.1M | 813.1M | 813.1M | 813.1M |
| Cash burn (monthly) | 12.3M | (positive/no burn) | 147.1M | 96.89M | (positive/no burn) | (positive/no burn) |
| Cash used (since last report) | 49.39M | n/a | 590.63M | 389.04M | n/a | n/a |
| Cash remaining | 763.71M | n/a | 222.47M | 424.06M | n/a | n/a |
| Runway (months of cash) | 62.1 | n/a | 1.5 | 4.4 | n/a | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Jun 21 | Robert J Coury | Common Stock | Payment of exercise | Dispose F | No | No | 14.36 | 123,950 | 1.78M | 1,509,637 |
| 24 Jun 21 | Robert J Coury | Common Stock | Option exercise | Aquire M | No | No | 0 | 250,000 | 0 | 1,633,587 |
| 24 Jun 21 | Robert J Coury | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 250,000 | 0 | 0 |
| 21 Jun 21 | Harry Korman | Dividend Equivalent Units Common Stock | Grant | Aquire A | No | No | 0 | 101.154 | 0 | 101.154 |
| 21 Jun 21 | Kilts James M | Dividend Equivalent Units Common Stock | Grant | Aquire A | No | No | 0 | 101.154 | 0 | 101.154 |
| 21 Jun 21 | Richard A Mark | Dividend Equivalent Units Common Stock | Grant | Aquire A | No | No | 0 | 101.154 | 0 | 101.154 |
| 21 Jun 21 | Melina E Higgins | Dividend Equivalent Units Common Stock | Grant | Aquire A | No | No | 0 | 101.154 | 0 | 101.154 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
75.3% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1048 |
| Opened positions | 154 |
| Closed positions | 254 |
| Increased positions | 259 |
| Reduced positions | 521 |
13F shares |
Current |
|---|---|
| Total value | 12.71B |
| Total shares | 910.45M |
| Total puts | 14.37M |
| Total calls | 7.31M |
| Total put/call ratio | 2.0 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 129.46M | $1.81B |
| BLK Blackrock | 91.47M | $1.28B |
| Wellington Management | 65.79M | $919.07M |
| STT State Street | 52.75M | $736.92M |
| MCQEF Macquarie | 43.24M | $604.06M |
| Davis Selected Advisers | 41.29M | $576.82M |
| Laurion Capital Management | 31.46M | $439.54M |
| Geode Capital Management | 22.82M | $318.04M |
| Capital World Investors | 17.24M | $240.81M |
| Deerfield Management | 17.22M | $240.62M |
Financial report summary
?Management Discussion
- (1)Currency impact is shown as unfavorable (favorable).
- (2)The constant currency percentage change is derived by translating net sales or revenues for the current period at prior year comparative period exchange rates, and in doing so shows the percentage change from 2021 constant currency net sales or revenues to the corresponding amount in the prior year.
- (3)For the three months ended March 31, 2021, other revenues in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $22.3 million, $1.4 million, $0.4 million, and $6.1 million, respectively.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
AB, abbreviated, abroad, Abstinence, Abu, accessible, accretion, accrual, accumulated, actuarial, adding, Additionally, adequate, Administration, administrative, adverse, advisory, advocacy, affiliated, affirmative, affirmed, affordable, aforementioned, Africa, age, agent, agreed, aid, allege, alleged, allegedly, alleging, alternative, amid, Amitiza, amortizable, analog, annum, anticompetitive, antiviral, AOCE, API, appeal, appealed, April, arise, arising, ASC, Asia, assert, asserted, asserting, assessed, assessment, assigned, assignee, assurance, ASU, atrophy, Attorney, attract, Australia, average, Aviv, bank, Basic, began, beginning, belief, bellwether, bioequivalent, Biogen, biologic, biosimilar, Book, breach, bring, bringing, broad, broader, broker, brought, budgeting, calendar, California, call, Canada, capacity, Carolina, carryover, case, CAT, category, causation, Celebrex, Central, cerebellar, certification, certified, challenge, challenged, challenging, channel, charge, charged, chief, children, China, Circuit, circumstance, Citalopram, civil, CJEU, claim, claiming, Clarifying, classification, clean, clinical, CMA, coal, Code, collaboration, collateral, Columbia, commercial, commercialization, commercialize, commitment, committed, Committee, Commonwealth, comparison, compensate, compensation, compensatory, competing, competition, competitive, competitively, complaint, complemented, compliance, component, computation, computed, Connecticut, constant, consumer, consuming, context, contingent, contra, contract, Conversely, conversion, conveyance, cooperating, costly, counterclaimed, counterparty, country, County, court, covenant, coverage, COVID, Creon, criminal, criteria, critically, curve, customer, DCGI, dealer, dealing, decide, decision, declaratory, decommissioning, deemed, default, defeasance, defend, defendant, defense, deferred, degree, deliver, delivery, demonstrate, Department, deploying, depreciation, derecognized, develop, developed, developing, development, developmental, device, Dhabi, difficult, digital, Dilantin, dimethyl, direct, directed, directing, director, disagree, discharged, discontinue, discontinuing, discovery, discretion, disgorgement, dismissal, dismissed, dismissing, dispensing, disposition, dispute, distributor, District, diverse, diversified, divest, divested, divided, dividend, dividing, Division, DOJ, domiciled, dosage, dose, downsize, Dr, driven, drug, dry, Dymista, earlier, East, Eastern, EBITDA, EDPA, educate, Effexor, efficiently, effort, Eleventh, Eli, eligible, eliminated, eliminating, elimination, employee, empower, enabling, encouraged, energy, England, English, enhance, enhanced, enrichment, ensure, enterprise, entrance, entry, environment, EpiPen, equipment, equitable, essential, EU, Europe, European, event, evidence, evolving, exacerbation, examination, exceed, exclude, excluded, excluding, exclusion, exclusive, exclusivity, exemplary, exercisable, exercise, exercised, expand, experienced, experiencing, expert, expertise, explained, explore, exposure, expressly, extra, face, facilitating, Facilitation, facing, fact, factoring, failure, false, FASB, favor, favorable, favorably, FD, FDA, feasible, field, fifty, fight, fine, fined, fixed, Florida, flow, fluctuate, focused, Food, footprint, foreseeable, forma, formal, formulation, forward, fourteen, France, franchise, Frankfurt, fraudulent, French, fumarate, fundamental, gain, geographic, geography, GIC, Gilead, glargine, GmbH, goodwill, grant, granted, greater, harbor, harm, headquartered, healthier, hedge, hedged, hedging, high, higher, home, Hong, hospital, hospitalized, Hyderabad, iconic, implement, implementation, implemented, implied, important, improve, improved, incentive, incorrect, increasingly, incremental, incurrence, indemnification, indemnify, indenture, India, indirect, individual, individually, industry, infringe, infringed, infringement, infringing, ingestion, inhaler, injection, injunction, injunctive, injury, inquiry, insignificant, instituted, insulin, insurance, intangible, intellectual, intention, intercompany, intersegment, intrinsic, invalid, inventory, investee, investigation, investigational, investigative, IPR, Ireland, irregular, IRS, Israel, issuer, January, JANZ, Japan, Jersey, jointly, judgment, Justice, KBC, key, KGaA, Kingdom, Kong, label, lack, Lansforsakringar, largest, launch, launched, lawsuit, lead, leading, legacy, length, lesser, leverage, leveraging, Levothyroxine, liable, LIBOR, license, licensed, licensing, light, likelihood, Lilly, Lipacreon, Lipitor, live, LLC, local, location, London, long, longer, lost, low, lowest, LTIP, Lyrica, MA, machinery, maintain, maintained, maintaining, maintenance, maker, mandatory, margin, master, matter, maximize, maximum, MDL, Medicaid, medical, medicine, meet, melanoma, member, Merck, merged, merger, merit, met, methodology, metric, mg, middle, milestone, minimize, minimum, Minnesota, misleading, mission, Mississippi, Missouri, Mizuho, model, monthly, Morgantown, motion, moved, MPI, MUFG, multiple, Mutual, MYL, NaN, necessarily, negative, negatively, negligence, negotiation, Neonatal, neuropathic, NHS, nitrosamine, nonvested, North, Northern, Norvasc, notice, notional, notwithstanding, nuisance, occurrence, offset, offsetting, Ohio, open, opened, opening, opioid, optimally, optimization, optimize, option, Orange, ordinary, OTC, overcome, overhead, overlap, owner, pain, paper, paragraph, paramount, pari, Paroxetine, passu, patent, patented, pay, pen, penalty, penetration, Pennsylvania, people, percent, percentage, Perindopril, person, personal, personnel, pertaining, petition, pharmacy, Pharmascience, phase, pipeline, Pittsburgh, placement, plaintiff, plant, platform, play, pleading, PMS, point, policy, political, portfolio, portion, posed, post, powder, practice, prefilled, pregabalin, prejudice, preliminary, premium, prepaid, prescribed, prescription, preserve, President, prevailing, preventing, prevention, primary, principle, priority, privacy, proceeding, procurement, produce, professional, profit, profitability, program, promised, promotional, property, proprietary, prospective, protect, protecting, protection, provision, PTAB, Puerto, punitive, purported, purportedly, qualify, qualifying, Qualitative, quality, Quantitative, ramped, Ranbaxy, range, ranging, raniditine, ranitidine, rank, rapid, ratio, reached, rebate, recasted, reclassified, recognize, recognized, recommendation, reconciliation, recourse, Reddy, reduction, refer, reference, referenced, refined, refund, Reg, region, Regional, regular, reimburse, reimbursement, relief, relocation, remanded, remdesivir, remediation, remote, remuneration, rendering, rent, repatriation, request, research, reserve, reserved, resilient, resolution, resolve, resolved, resolving, resource, resourced, respiratory, Rest, Restated, restitution, restructuring, retail, retirement, retrospectively, revenue, rico, role, rollforward, routinely, royalty, safe, safeguard, sale, Sandoz, Sanofi, SAR, satisfy, scheduled, scientific, Scotland, Scottish, SDNY, seasonality, Secretary, secure, secured, securing, securitization, security, segment, SEMGLEE, sensitive, serve, service, settled, settlement, Shanghai, shift, shown, significantly, simplify, simplifying, site, size, Skandia, Sodium, solid, sought, source, South, Southern, span, speaking, split, sponsor, sponsored, spot, stage, standard, standardized, statutory, stayed, stipulated, stockholder, strategy, strong, strongly, structurally, structure, structured, study, subordinated, subpoena, substantive, substitute, substitution, sue, sued, suffered, sufficient, summarized, summary, superior, supplement, supplemental, supplier, support, supporting, Supreme, survival, sustainable, sustained, Syndrome, system, Taiwan, tangible, Tecfidera, technology, Tel, tender, tentative, Teva, therapeutic, thereof, threatened, timeframe, top, Topic, trace, trailing, transformation, transparent, treatment, Treaty, trial, true, TSA, twelve, type, typically, unadjusted, unallocated, uncollectibility, underbidding, undergone, undertook, unfavorable, unique, unjust, unlock, unmet, unparalleled, unpatentable, Unrealized, unrecognized, unsuccessful, unusual, unvested, urgent, usage, utilize, utilized, utilizing, validation, validity, valsartan, variability, variable, variety, vast, VBP, vest, vested, vesting, viable, Viagra, vial, view, viewed, vigorously, violated, violation, Virginia, voidable, volume, website, weighted, West, Western, wholesaler, wholly, wide, win, wind, winning, work, workforce, working, worldwide, Xanax, yield, York, Yupelri, Zealand, Zoloft
Removed:
aim, alerting, amplify, analytical, assume, aware, capitalize, careful, Cautionary, cautioned, commodity, conducted, conformity, consult, corporation, creating, Delaware, duration, efficacy, emerge, expression, file, firm, free, funding, goal, heading, Holdco, identification, identify, inaccurate, incidence, incidental, incorporation, integral, jurisdiction, list, macroeconomic, materialize, mind, objective, ownership, par, partial, PCAOB, precipitate, prove, publicly, put, register, registered, Registration, relation, responsibility, responsible, set, speed, statement, stemming, strain, timely, tracking, transmission, understand, undue, unemployment, unknown, unqualified, vaccine, vary, varying, volatile, voting, widespread
Current reports
8-K
Entry into a Material Definitive Agreement
1 Jul 21
8-K
Other Events
17 Jun 21
8-K
Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend
10 May 21
8-K/A
Cost Associated with Exit or Disposal Activities
25 Feb 21
8-K
Results of Operations and Financial Condition
22 Feb 21
8-K/A
Financial Statements and Exhibits
29 Jan 21
8-K/A
Cost Associated with Exit or Disposal Activities
11 Dec 20
8-K
Entry into a Material Definitive Agreement
25 Nov 20
8-K/A
Entry into a Material Definitive Agreement
19 Nov 20
8-K
Entry into a Material Definitive Agreement
19 Nov 20
Registration and prospectus
S-8
Registration of securities for employees
20 Nov 20
8-A12B
Registration of securities on exchange
10 Nov 20
425
Business combination disclosure
26 Jun 20
425
Business combination disclosure
18 Jun 20
425
Business combination disclosure
16 Jun 20
10-12G
Registration of securities
12 Jun 20
425
Business combination disclosure
1 Jun 20
425
Business combination disclosure
29 May 20
RW
Registration withdrawal request
11 Mar 20
424B3
Prospectus supplement
13 Feb 20
Proxies
No filings
Other
EFFECT
Notice of effectiveness
14 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20
CORRESP
Correspondence with SEC
5 Feb 20
UPLOAD
Letter from SEC
2 Feb 20
CORRESP
Correspondence with SEC
16 Jan 20
UPLOAD
Letter from SEC
2 Jan 20
CORRESP
Correspondence with SEC
12 Dec 19
CORRESP
Correspondence with SEC
12 Dec 19
UPLOAD
Letter from SEC
21 Nov 19
UPLOAD
Letter from SEC
21 Nov 19
Ownership
4
Viatris / ROBERT J COURY ownership change
25 Jun 21
4
Viatris / Menassie Taddese ownership change
23 Jun 21
4
Viatris / Brian Roman ownership change
23 Jun 21
4
Viatris / Xiangyang (Sean) Ni ownership change
23 Jun 21
4
Viatris / Anthony Mauro ownership change
23 Jun 21
4
Viatris / Andrew Cuneo ownership change
23 Jun 21
4
Viatris / Rajiv Malik ownership change
23 Jun 21
4
Viatris / ROBERT J COURY ownership change
23 Jun 21
4
Viatris / MICHAEL GOETTLER ownership change
23 Jun 21
4
Viatris / Paul Campbell ownership change
23 Jun 21
Transcripts
Reddit threads
Stock Watch List July 29, 2021
29 Jul 21
Viatris ($VTRS) IMHO this 3pct div blue chip Pfizer pharma spinoff has bottomed and is starting a gradual rise to a target of $18 within 18 mo
28 Jul 21
Should Canadians buy US div stocks??
25 Jul 21
I've officially hit $40 CAD monthly let the compounding start!
24 Jul 21
Aggressive positions for about 4k I have lying around
19 Jul 21
Pfizer - Where I'm Hiding Out
19 Jul 21
Going shopping!
19 Jul 21
Zoetis Inc - A Speculative Analysis (NYSE: ZTS)
19 Jul 21
Best value dividend stocks?
18 Jul 21
Fellow Canadian Dividend Investors Where You at?
17 Jul 21